Thomas McLain
Plus aucun poste en cours
Fortune : 8 225 $ au 30/06/2024
Profil
Thomas H.
McLain served as the Chairman, President, and Chief Executive Officer of Nabi Biopharmaceuticals from 1998 to 2007.
He then became the Vice President of Bausch & Lomb, Inc. from 1988 to 1998.
McLain also held the position of Independent Director at Eastman Chemical Co. in 2011.
In 2013, he served as the President and Chief Executive Officer of Aspira Women's Health, Inc. McLain was the Chief Operating Officer and General Manager of Exosome Diagnostics, Inc. from 2014 to 2019.
Currently, he is the President of Renalytix Plc.
McLain received his undergraduate degree from the College of the Holy Cross (Massachusetts) and holds an MBA from the University of Rochester Simon Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RENALYTIX PLC
0,04% | 10/04/2024 | 59 150 ( 0,04% ) | 8 225 $ | 30/06/2024 |
Anciens postes connus de Thomas McLain
| Sociétés | Poste | Fin |
|---|---|---|
| RENALYTIX PLC | President | 30/04/2024 |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Directeur Général | 01/10/2015 |
| ASPIRA WOMEN'S HEALTH INC. | Directeur Général | 23/04/2014 |
| EASTMAN CHEMICAL COMPANY | Directeur/Membre du Conseil | 01/12/2011 |
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Directeur Général | 15/02/2007 |
Formation de Thomas McLain
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| EASTMAN CHEMICAL COMPANY | Process Industries |
| ASPIRA WOMEN'S HEALTH INC. | Health Technology |
| RENALYTIX PLC | Technology Services |
| Entreprise privées | 5 |
|---|---|
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
BioFlorida, Inc.
 BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013. | Commercial Services |
| Claro Scientific LLC | |
Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Health Services |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Health Technology |
